Benekou Katerina, Montoto Silvia
aDepartment of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom bEuropean Society for Blood and Marrow Transplantation (EBMT)-LWP, Paris, France.
Curr Opin Oncol. 2017 Nov;29(6):455-459. doi: 10.1097/CCO.0000000000000403.
Better understanding of the lymphoma pathogenesis and molecular biology has introduced a new era in the lymphoma therapy with the advent of targeted drugs. In this new era, the role of hematopoietic stem cell transplantation (HSCT) is evolving, and the purpose of this review is to demonstrate how the introduction of novel agents has affected the current treatment strategy of different subtypes of lymphoma.
Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed Hodgkin Lymphoma and high-grade non-Hodgkin lymphoma (NHL). In the group of the indolent lymphomas, ASCT maintains its role in the relapsed setting. Novel targeted agents like idelalisib and ibrutinib have shown to induce prolonged remissions with a very good safety profile. However, the follow-up is still relatively short and none of these drugs have demonstrated a curative potential, as opposed to HSCT.
For many authors, the advent of new targeted drugs is challenging the role of HSCT in different subsets of lymphoma. The actual challenge is how to make the best use of these drugs, in certain circumstances in combination with HSCT, to further improve the outcome of patients with lymphoma.
随着靶向药物的出现，对淋巴瘤发病机制和分子生物学的更深入了解开启了淋巴瘤治疗的新时代。在这个新时代，造血干细胞移植（HSCT）的作用正在不断演变，本综述的目的是阐述新型药物的引入如何影响不同亚型淋巴瘤的当前治疗策略。
自体干细胞移植（ASCT）仍然是复发霍奇金淋巴瘤和高级别非霍奇金淋巴瘤（NHL）患者的标准治疗方法。在惰性淋巴瘤组中，ASCT在复发情况下仍发挥作用。新型靶向药物如idelalisib和ibrutinib已显示出能诱导长期缓解，且安全性良好。然而，随访时间仍相对较短，与HSCT不同，这些药物均未显示出治愈潜力。
对许多作者而言，新型靶向药物的出现正在挑战HSCT在不同淋巴瘤亚组中的作用。实际面临的挑战是如何在某些情况下将这些药物与HSCT联合使用，以进一步改善淋巴瘤患者的治疗效果。
